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ABSTRACT 
Metabolism of labe led enantiomers of tryptopha n, kynurenine and hydroxykynurenine in to 
C 140 2 and nin e tryptophan metabolites was studied in five patients with scleroderma. T he 
D-isomers of tryptopha n, kynurenine a nd hydroxykyurenine were poorly converted to C0 2 
but did give rise to small amoun ts of activity in several of the urinary metabolites. T hese 
observat ions suggest that man may have D-a mino ac id oxidase and hydroxylase enzyme 
systems capable of convert ing small amou nts of the D- isomers into metabolites found in 
th e urine. However, on the basis of previously pub lished animal data, which showed a de-
layed abso rpt ion of the D- isomers from the intestine, it is not possible to exclude metabo-
lites ar is ing fro m action of the in test inal flora. With both the D- and L- isomers, the C 14 
activity isolated in known urinary metabolites accounted for only a mall part of t he total 
urinary C 14 activity. In several patients given 2 gms of L-tryptophan with C 14 labeled tryp-
tophan, ex piratory C "0 2 was depressed and urinary labeled quinolinic acid activity was 
elevated when compared to patients in previous studies. T hese factors suggest that some 
scleroderma patients may have an alteration of a metabolic step in the pathway after hy-
droxyanthranilic acid. Conclusive evidence of a relationship between amount of C ''02 pro-
duced after a 2 gm load of L-tryptophan a nd metabol ic abnormali t ies was not observed. 
The experiments showed t hat the racem ic mixture of a labeled tryptophan compound 
could be used for a C ''0 2 metabolism study, but t hat t he use of pure, natural L-isomers is 
necessary for meaningful results in the study of tryptophan metabolism in man. 
Racem ic mixtures of labeled compounds are 
common ly used in metabo li c stud ies because they 
are more readily avai lab le than the resolved D- or 
L-isomers. Previous work with the labeled D- and 
L-isomers of kynurenine, hydroxykynurenine and 
tryptophan has shown that the rat and mouse 
metaboli ze the enantiomers of these compounds 
into C"0 2 at different rates (1 , 2, 3). The rat does 
not metabolize the D -isomers of kynurenine or 
hydroxykynurenine efficiently, but it can utilize 
the D- a nd L-isomers of tryptophan equa ll y well. 
Therefore, a ny study with the DL mixture of 
these compounds can lead to difficult or erro-
neous in terpretations in some a nima l spec ies be-
cause of t he unusual or abnormal metaboli sm of 
the unnatural isomer of the mixture. T his study 
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was undertaken to compare the metaboli c pat-
terns of the D- and L-isomers of tryptophan-7a-
C '', kynurenine -keto -C 1 ' , and 3-hydroxykynu -
renine-keto-C '' in patien ts with scleroderma . 
Patients with scleroderma were chosen as sub-
jects for investigation for three reasons. First, 
they p rovided an opportunity to compare metabo-
li sm of tryptophan isomers in humans. Second, 
they provided an opportunity to evaluate certa in 
aspects of tryptophan metaboli m in scleroderma 
in which aber rations have been reported (4, 5). 
T hi rd, we wished to check the observation that 
giving a 2 gm load of carrier tryptophan with a 
dose of C "-labe led tryptophan produced a n ap-
preciable increa e in the amount of C" expired as 
C "0 2 (6). If this observat ion were confi rmed, the 
2 gm loading do e of L-tryptophan given with t he 
labeled material might provide a useful diagnostic 
method for clinica l detection of aberrati ons in 
tryptopha n metaboli m. 
MATERIALS AND METHOD 
Two types of stud ies were done on patients. The excre-
tion of trypt ophan metabolites was measured quantit·a-
tively before and after loading with 2.0 gm of L-trypto-
phan or l.O gm of D-t.rypt.ophan. At t he same time. 
these subjects were given small tracer d9ses of labeled 
tryptophan in order to assess the metabolism of the la-
beled compound under these loading cond itions. Severa l 
of the patients were stud ied again at a later date with 
tracer doses of D or .L-kynurenine or 3-hydroxykynu-
reni.ne. Thus, they erved as t.heir own control s. Studies 
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a re sum mari zed in Tab le I, whi ch gives pert inent data 
of pat ient information, and doses of unlabeled a nd la-
beled compounds administ ered . 
All patients gave their informed consent. For a period 
of five days prior to and durin g the study period , the 
patients received a cont rolled t ryptophan diet con-
ta ining 0.7 to 1.0 gm per day. All form s of drug therapy 
were avoided durin g th e study period , and all studi es 
were done with pat ien ts in the rest ing sta te. Labeled 
compounds were given orally in gelatin ca psules one 
hours afte r breakfast. The 2.0 gm " loading" doses of L-
t ryptophan were administered at th e sa me t im e as the 
tracer doses, when indi cated. 
DL-tryptophan -7a-C " a nd OL-tryptophan -2- C" 
(Tracerlab Inc., Waltham, Mass.) used here were homo-
geneous as determined by autoradiography of paper 
chromatograms. T he OL-kynurenine-keto-C" and the 
3-hydroxy-DL-kynurenine-keto-C " were synthesized in 
our labora tori es (7, 8). The DL-tryptophan-7a -C ", OL-
kynurenin e- keto-C " a nd 3- hydroxy-D L-kynurenin e-
keto-C" were resolved in to the D and L-isomers by a 
paper powder column techn ique (Hankes, L. V. , Kido, 
R. a nd Brown , R. R.: Unpublished procedures.) The 
specific act ivit ies were determined by combustion to 
C0 2 and ana lys is in Ba llentin e gas coun t ing tubes (9) . 
Urine sam pl es were collected for a 24-hour period 
prior to the ad ministrat ion of a labeled compound and 
for three consecutive 24 -hour periods thereafter. Uri ne 
specim ens were co llected under to luene in da rk glass 
bottles and stored in the cold un ti l the coll ect ions were 
completed. Total volum e was measured and the urine 
stored frozen in plastic bottles until analyzed. 
Twenty -four hour urine samples collected before and 
after admini stra tion of compounds were analyzed for 
twelve co mponents by chemica l ( 10) or microbiologica l 
methods (11 , 12). The components determined were 
kynurenic ac id , xa n thureni c acid, a nthranili c ac id glu -
curonid e, o-aminohippuri c ac id, acetylkynurenine, an-
thranili c ac id , kynurenin e, 3-hydroxy kynurenine, N '-
methy!ni cotin a mid e, N ' -methy l-2- pyrid one-5 -ca rbox -
amid e (10). quinolinic ac id ( ll), and ni cotinic acid (12). 
For comparison, the sa me meta boli tes were measured, 
using the sa me methods, in healthy control wo men con-
sisting ma inly of laboratory personn el (10). 
The majority of th e meta bolites measured were also 
isolated from the C " -labeled urine collections by carrier 
tec hniques app lied to appropriate .fractions from the 
ana lyt ical columns, recrystallized to constant specifi c 
act ivi ty and counted by the method of Van S lyke, 
Steele and Plazin (9). The urinary components isolated 
were o-a minohippuri c ac id, kynurenic acid, xanthurenic 
acid kynurenin e, 3-hydroxy kynurenine, N '··methylni co-
ti na~ id e (1 , 10) , quinolini c ac id, nicotinic ac id (13) 
and picolinic ac id (14). Radioactivity in kynurenine and 
acetylkynurenin e was a lso dete rmin ed by liquid sc in ti l-
lat ion countin g of steam volat ile o-a minoacetophenone 
derived from a lkaline stea m dist illation of raw urine 
(15). Aliquots of each uri ne were digested with comm er-
ical urease and the C"O, liberated from the urina ry 
urea was tra pped in ethanolamine and measured by 
liquid sc intillation counting. 
Crysta lline D-tryptophan and 0 -kynurenine car ri ers 
were isolated from the 6- 12 hour and 12- 24 hour urines 
of patient G-7, (Tabl e II) , who received D-tryptophan -
7a-C". This was done by streaking 0.5 ml of the 6- 12 
hour urine or 1 ml of the 12- 24 hour urine on sheets of 
No. 4 Whatman paper foll owed by development with a 
solvent system of methanol, benzene, bu tanol and water 
2: 1: 1 :1 to whi ch was added l ml of glacia l acet ic ac id 
per 100 ml of solvent . Autoradiogra phs of the paper 
chromatograms showed an in tense black band at Rf 
0.55. This labeled band was cut out from two of the 
chrom atograms. T he strips were fin ely divided and sus-
pended in a b lender with 50. 35 mg of D-tryptophan or 
47.57 mg of 0 -kynurenine and wate r. The solu t ions were 
f:i ltered through sinterecl glass funn els and concentrated 
to dryness with a rota ry eva porator. The res idues were 
recrystalli zed to constant specifi c act,ivities. 
Sa mpl es of a ir ex ha led by the pat ients were coll ected 
by mea ns of a p last ic hood fitt ing over the pat ient 's 
head and connected by large diameter p lastic tubing to 
a set of glass absorption towers arra nged in para llel, 
such that the a ir fl ow would pass through one column at 
a t ime. Fifteen minu te co llect ions of CO., were made by 
switching the a ir fl ow from one glass absorption tower 
to the other. Each absorpti on tower has a ca pacity to 
absorb more than 30 minutes of average CO, produc-
tion. The a ir was pu ll ed through the syste m at a rate 
whi ch assured t ra ppin g of the CO , in the 2N NaOH 
solut ion in the absorp tion tower and, at the sa me t ime, 
kept the patien t co mforta ble. The sodium hydroxide 
sa mples were analyzed for C " activity by ac idification 
in a Van S ly ke-N eill chamber, followed by transfer of 
the liberated CO 2 gas in to Ballentin e gas count ing 
tubes. The CO, sa mples (fifteen minute) were coll ected 
continuously for a four-hour peri od and then at two-
hour intervals. The following equations were used to 
ca lculate the perce nt of administered c· · ex pired as 
C "0 , per minute: 
11 c-C " / mmole CO , x body surface a rea (M 2 ) x 4.8 
11c-C •• produced/minute 
-------- X LOO 
11 c-C" ad ministered 
~ 11 c-C " / min 
~ % dose ex pired/ minute 
The va lue of 4.8 is the mea n normal millimoles of 
CO, ex pired by rest in g human subjec ts per minute per 
square meter of body surface, according to Consolazio. 
Johnson and Pecora ( 16). 
RESULTS 
Some of the pathways of tryptophan metabo-
lis m in a nima ls a re s hown in Figure 1. The la-
be led p osition s of t h e several compounds used in 
these studi es and the kn own m etabolic rou tes to 
t h e compounds isolated are indica ted . 
General info rmation a bout th e pa t ien ts and 
d ose leve ls are g iven in Tab le I. Five fe male pa-
ti ents were studied, in som e cases wi t h m ore than 
on e labe led compound . 
Table II shows the la be led compounds given 
a nd the percent of the d ose exc reted in th e urine. 
Most of th e urinary activity from the compounds 
a ppea re d in the first 0- 12 and 0- 24 h our period. 
Data from urine coll ections divid ed inLo 0- 6 a nd 
6- 12 hour periods (patients C-6 a nd G-7) suggest 
that D -try p to pha n is h and led diffe rentl y tha n the 
L- isomer. 
Tab le III shows the quantitative excretion of 
urinary tryptophan m eta bolites. Any result above 
or be low m ean· contro l va lues by more t ha n two 
sta ndard dev iat io ns was co ns ide red a bnorm a l. 
Patient C showed a normal urinary m eta boli te 
pattern whe n g iven the first load test (C-1) . How-
T
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TABLE II 
Urinary excretion. of carbon-14 from scleroderma patients administered labeled try ptophan. m etabolites* 
ComJHlund~ Urine co llec tions 
Patient Tryptophan Labeled luod () 24 h r.;. 
A-1 OL-Try ptopha n-2 2.0 gm- L 35.53 
B-J OL-Tryptophan-2 2.0 gm-L 30.67 
C- 1 OL-T ryptopha n-2 2.0 gm-L 33.21 
0 -1 OL-Tryptopha n-2 2.0 gm -L 37.38 
0-2 L-Ky nurenine- Keto None 42.56 
B-2 L-Kynurenine- Keto None 12.30 
0- 12 hrs. 12- 24 Ius. 
B-3 Hydroxy -L-Kynurenin e-Keto None 24.88 0.5 1 
C-4 0 -Kynurenin e-Keto None 59.44 9.35 
C-5 Hydroxy- 0 -Ky nureni ne- Keto None 74.66 5.40 
0- 6 hrs. 6- 12 hrs. 
C-6 L-T ryptophan -7a 2.0 gm -L 3.43 1.09 1.23 
G-7 0 -Tryptophan -7a 1.0 gm-0 4.04 48.07 9.38 
• All va lues a re percent of dose given. 
8'\ 
~COOH 
~NH2 I anthranili c acid 
~,-8 
C - N-C H -COOH I 2 
NHz H 
o- ominohippuri c acid 
l 0 
II 8 _yD 
CH2 -C H-COOH 
I -2 NHz 
OH 3 - hyd roxykynurenine 
C02 - CH3 - CH -COOH A 
kynurenic aci d 
OH 
~ ~D v~~COOH 
OH 
xonlhuren •c OCid 
fo ( o ~~C080H 
NH ~ NHz 
~ 2 OH 3- hydroxyo nlhronil• c o c•d 
8/f 
[ 
C02 ~ ( 8 ~Hl ~COOH 
H -C ~c~ NH H- C ~NH~ 
/ II 11 ' 0 H II 11 'QH 0 ~ a - ami~o -g -c arboxy - , -gl ut orol e 
COOH pa thwa y muconic se miotde hyd e 
. Nl " . ,_ ... , ) 
f8 ~COOH 
~~jlcooH 
\ quinalin ic acid 
[
QU IO OIIni C J 
r •b onu cleo t•de 
\: PICa 1n1 c A C0 2 ;'8 
n I CO li n0m1d e 
I n iaCin J L_r • bonucleol•de acid 
4 
~g-NH 2 -NAO,NADP-
(8 ~8 ~COOH N H3 ~t-NH 2 ~{~NH2 
N ~jl 0 -- rf)'-r/ 0 
nico t inic I r 
acid CH3 CH3 
NLme th yl -
ni co tinamid e 
N 1 - mc th y l -
2- pyridone -
5 - corboxomide 
14 - 48 hr!i. ·18- 72 hr.;. 
3.29 0.52 
3.37 0.31 
1.53 0.20 
l.82 0.29 
2.20 0.87 
1.23 0.68 
0.15 0.07 
2.25 1.02 
0.90 0.49 
l.57 0.60 
4.64 0.44 
F IG . l. Lette rs a re give n to the labe led ca rbons of" t h ad ministered co mpou nd a nd these lette rs indi ca te the fate 
of" a pa rticu la r ca rbon down through the pathway. T he lette r A refers to the ca rbon la beled in the tryptopha n-7a-C "· 
The letter 8 refers to the ca rbon labe led in kynurenin e- keto-C" a nd hydroxykyn urenine- keto-C ".The le tter D refe rs 
to the ca rbon labeled in l.ry ptopha n-2- C ' '' . 
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ever, when she was given the load test several 
years later (C -6) with the labeled tryptophan-7a-
C 14 , she showed abnormal levels of kynure nic ac id , 
xanthurenic ac id, and kynuren ine. 
Patients B-1 and D-1, when given DL-trypto-
pha n-2-C" plus a 2. 0 gm load of L-tryptophan, 
showed s imilar low C "02 curves (Fig. 2). How-
ever, the tryptophan metabolite levels in their 
urines were different. The urinary metabolite 
levels (Table III) of patient B-1, after a t rypto-
phan load, were normal with the exce ption of low 
MPCA va lues, whereas patient D-1 showed ab-
normally high levels of kynurenic acid, xanthu-
renic ac id , acetylkynurenine, kynurenine, and 3-
hydroxykynurenine. Assum ing that t he normal 
range of urina ry quinolinic acid for females is the 
same as for males, patient D-1 a lso had a high 
quinolin ic ac id leve l. It is of interest to note that, 
at a later date, when pa ti ents Band D were given 
a tracer dose of L-kynurenine- keto-C 14 with no 
loading dose of L-tryptophan (B-2 and D-2), no 
a bnormal leve ls of metabolites were observed by 
chemical assays. However, when the quantities of 
C" activity in each component were measured, 
differences ap peared as shown in Table IV. Sub-
ject D-2, who was marked ly abnormal in response 
to the 2.0 gm load of L -tryptophan, was a lso 
marked ly different in response to the tracer dose 
of L-kynuren ine when compared to subject B-2. 
Table IV shows the percentage of the labe led 
dose excreted in the urin e as la beled tryptophan 
metaboli tes and urea. When L-kynurenine-keto-
C 1 • was given to patient B-2 or D-2, the largest 
percentage of the dose appeared in the label ed 
qu inolini c ac id , 3-hydroxykynurenine, and kynu-
renic acid fractions, with the levels of these com-
ponents in the urine of pat ient D-2 being two to 
tour times higher tha n those of patient B-2. S ince 
the levels of quinolinic ac id were so high in the 
fi rst ·24-hour urine of these pa tients, quinolinic 
and nicotini c acids were a lso isolated from their 
24- 48 hour and 48- 72 hour urine specimens. La-
be led quinolini c acid levels in the 0- 24, 24- 48 and 
48- 72 hour urines of patient B-2 were 2.27%, 
0.25% and 0.08% compared to 4.39%, 1.10% and 
0.28% fou nd in the urines of patient D -2. These 
data showed t hat patient D-2 excreted about 
twice as much rad ioactivi ty in the form of quino-
linic ac id as patient B-2 for each of the three 
days. The labe led nicotinic ac id levels showed a 
similar relationshi p in these urines. These data 
may refl ect a lowered vita min B 6 activity in some 
of the later s teps of the pathway in patient D-2 
s in ce prev ious work has shown an increased ex-
cretion of quino lin ic acid in a vitamin B. defi -
ciency (17- 20) . The major labeled metaboli tes of 
3-hydroxy-L-kynurenine-keto-C 14 in pat ient B-3 
urine were qu inolini c ac id and xa nthurenic ac id . 
Pat ient C-6, who rece ived L-tryptophan-7a-C 1 ', 
excreted picolinic ac id and kynureni c acid as the 
major labe led urinary metaboli tes. 
Patient C-4, who was given the D-kynurenine-
keto-C 14 , exc reted kynurenin e, hydroxy kynu -
renine, kynureni c ac id and N 1-methy lnico-
tinamid e as major labeled urina ry componen ts. 
Patien t C-5, t he rec ipient of 3-hydroxy-D- kynu-
renine-keto-C 1 4 , exc reted the most activity in 3-
hydroxykynurenine, xanthurenic ac id , quinolinic 
acid and picolinic ac id . On the basis of the figures 
in Table IV, one would assume that kynurenine 
was the major labeled component in the urine of 
patient G-7, who received D-tryptophan-7a-C ". 
However, when the 6- 12 and 12-24 hour urines 
from patient G-7 were chromatographed and the 
chromatogram autorad iographed, an in tense band 
showed at Rf 0.55 . The t reatment of this band 
with either carrier D-tryptophan or D-kynurenine 
showed that a ll of t he ac tivity from the spot was 
in D-tryptophan, which accoun ted for 31.67% of 
the dose in the 6- 12 hour urine and 4.4% of the 
dose in the 12- 24 hour urine. 
T he va lues in T a ble V show that, even though 
nine co mponents were isola ted from the urines, 
we only accoun ted for a minimum of 1.32% to a 
max imum of 71.31% of the urine activity in any 
particular study. T he urine of patient C-4, who 
received D-kynurenine- keto-C 1 ", conta ined 4.86% 
of the activ ity present in hydroxykynure nine and 
2.68% in kynurenic acid , which suggests that the 
human has a kynurenine hyd roxy lase capable of 
hydroxylati ng D-kynurenine, and a D-a mino acid 
ox idase whi ch ca n conve rt D-kynurenine to an a-
keto ac id that sponta neously cyclizes to kynu-
renic ac id. Quinolinic ac id accoun ted for 5.5 to 
18.5% of the ur inary ac tivity in a ll the patients 
given a n L-isomer. Kynurenic ac id represented 
1.0 to 5.8% of the urine activity in the urine of 
those patients rece iving D or L-kynurenine. P ico-
lini c ac id accoun ted for the largest percentage 
(7.28) of act ivity present in the urine of the pa-
t ien t given L-tryptophan -7a-C 14 • 
When labeled kynurenine analyses were done 
by the di stillat ion of t he a min oacetophenone 
formed from a lka lin e hydrolys is of urinary kynu-
renine, the values were four to ten times higher 
tha n the va lues obta ined by carrier method in 
those urines from the patients given D or L-kyn-
urenine- keto-C 14 (Table IV). Apparently, the car-
ri er method measured the free urina ry kynure~in e 
levels, and the di st illation methods gave the con-
jugated plus free kynurenine in the urine. 
As shown in Figure 2, when tryptophan-2-C" 
was given to t he scleroderma pat ients with the 2.0 
gm load of L -tryptophan, the product ion of C 1 '10 2 
was less than the 22- 24% observed in previous 
studies in a ll patien ts except pat ient A-1 (6) . T he 
patients with the lowest outpu t of C "0 , seemed 
to have the most severe scleroderma from a clin-
ica l viewpoin t. There was an apparen t re lation-
ship between rate of C "0 , production after a 
la beled tryptophan load and the aberrations in 
t ryptopha n metaboli s m observed. 
Figure 3 shows a .time lag of about one hour 
before the C"O, a ppeared in the breath of those 
patients rece iving L-tryp tophan-7a-C 14 with the 
2.0 gm load of L- t ryptophan, L-kynurenine-keto-
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TABLE IV 
Tw e nty-fou r hour excretion of C1 ' labeled metabolites in urine af ter the administration of labeled enantiomers of 
tryptophan, l1ynuren.ine and hydroxyhynurenine* 
Puticn t G-i C-G C-4 C-.5 B-2 B-~ 0 -2 
0 - L- 0 - 0 - L- L· L-
C 14 L.uiJclcd com pound g:i\'cn try pt oph::m - tr~· ptophnn · kynurenine- hydroxy- kynurenine- h\'droxv- kynurenine-
7n -C 11 7n-C 14 kcto-C' ' kynurenine- kcto-C •• ky•-lurenfnc- keto-c •• kct·o-C•• keto-C• • 
0 -Am ino hippuric ac id 0.008 0.093 0.033 0.007 0.072 0.013 0.065 
Kynuren ic ac id 0.025 0.220 1.840 0.018 0.217 0.003 0.405 
Xanthurenic ac id 0.003 0.036 0.038 0.490 0.038 0.204 0.280 
Ky nurenine (d isti ll ed) 0.646 0.03 43 .61 0.00 1.448 0.00 3.201 
Kyn urenine (ca rri er) 0.600 0.148 10.05 0.073 0. 105 0.102 0.396 
Hyd roxy kynurenine 0.036 0.038 3.340 0.887 0.156 0.1 35 0.870 
Qui nolini c ac id 0.018 0.318 0.048 0.1 45 2.269 3.707 4.392 
N icotini c ac id 0.001 0.003 0.003 0.004 0.01 1 0.012 0.028 
N 1-methyl Ni cotinamide 0.049 0.051 0.131 0.04 ' 0.02 0.025 0.052 
P icolinic acid 0.022 0.4 19 0.005 0.135 0.008 
U rea 0.006 0.391 0.008 1.180 0.608 0.550 
Total recovered '!' 0.814j: 1.599 49.048 1.737 5.4 11 4.715 9.843 
* Va lues a re percent of dose given. 
t Tota ls are based on the di stilled kynurenine values rather tha n ca rrier va lues, since the disti llation method a lso 
detects acety l kynurenine a nd other possible conjugates. 
:t: An additional 36.07 perce nt of the tota l dose was accou nted for as unmeta bolized 0 -tryp tophan in the urine. 
TABLE V 
Lab eled urinary metabolites as percent of urinary carbon-14 
Putic nt G-i C-G c .. 1 C-ii B-2 B-:l 0 ·2 
0 - L- 0 - 0 - L- L- L-
Compound g: ivcn t ryp tophnn- trypt ophnn - kynurenine- hydroxy- kynureni ne-
hvdroxv- kynurenine-
7n -c• • 7n-C•• kctn-C• • kynurenine- kcto-c• • kyi,urcnlnc - kcto-C' I I kcLo-C 1 ' kct o-C • ~ 
0-Amino hippuric ac id 0.012 1.619 0.048 0.008 0.582 0.04 2 0.152 
Kynurenic ac id 0.040 3.831 2.677 0.022 1.765 0.011 0.951 
Xanthureni c ac id 0.005 0.629 0.055 0.613 0.311 0.682 0.658 
Kynurenine (distilled) 1.05 0.53 63.4 0.00 9.33 0.00 7.52 
Kynu renine (carrier) 0.975 2.581 14.62 0.092 0.852 0.339 0.931 
Hydroxykynurenine 0.058 0.656 4.859 1.108 1.267 0.450 2.044 
Quinolini c ac id 0.029 5.516 0.07 0.181 18.45 12.382 10.32 
Nicotini c ac id 0.001 0.052 0.004 0.005 0.09 0.04 0.065 
N 1-methyl ni cotinamide 0.080 0.882 0.191 0.054 0.165 0.083 0.122 
Picolinic acid 0.036 7.283 0.007 0.168 0.026 
Urea 0.01 6.80 0.01 9.60 2.40 1.30 
Tota l percent of urinary ca rbon- l.32li 27.798 71.311 2.169 41.560 16.455 23.132 
14 recovered* (0- 24 l1rs. ) 
* Tota ls are based on distilled kynu renine va lues. Thi s method a lso detects conjugates of kynurenine. 
tAn additi ona l 62.79 percent of the tota l was accounted for as unm etabolized 0-tryptopha n. 
C'\ or 3-hyd roxy- L-kynurenin e-keto-C 1 ' . T he 
patient (C -6) given L-trypto phan-7a-C 1 ' with the 
2.0 g m load of L-tryptophan produced 28% C "0 , 
which was compa rable to the 32% level observed 
in rats given the same dose on a body we ight 
basis (3) . 
Figure 4 shows a slightly longer t ime lag be-
tween administration of D-isomers and appear-
ance of C 14 0 2 in expired ai r of patients, when 
compared with those receiving L-isomers (Fig. 3). 
The level of C"0 2 produced by the patien ts re-
ceiving D-tryptophan-7a-C 1 4 plus 1.0 gm D-tryp-
tophan, D-kynurenine-keto-C 14 or 3- hydroxy-D-
kynurenine- keto- 1 4 was less tha n 2% in each 
case. 
DISCUSSION 
In these studies, t here was a t ime delay of sev-
era l hou rs in the produ tion of the C 140 2 from D-
tryptopha n, as compared with "0 2 production 
from L-t ryptophan. Previous studies have shown 
that some D-isomers were not actively trans-
ported by ra t intestine (21, 22). With delayed 
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F IG. 2. Expirat ion or c ''0, by sclerod erma patie nts afte r ora l adm inis tration or t racer closes or DL-tryptopha n-2-
c" with loads of L-tryptopha n. 
absorption, it is poss ibl e that in testinal fl ora 
could play a role in the metabo lism of these iso-
mers. The delay in the a ppearance of C ''0 , when 
the D- isomers were give n is refl ected in the C" 
co ntent of the urine where the la rgest quantity of 
activity appea red in the 6- 12 hour period a fter D-
t ryptopha n ingest ion. So me of this could be D-
kynurenine fo rmed by the enzy mes in the intes-
ti na l mucosa. Yamamoto and Haya ishi (23) have 
shown that the rabb it in test ina l mucosa conta ins 
an oxygenase capable of conver t ing D-trypto phan 
in to D-kynurenine. 
T he activ ity present in the urinary components 
(other than D-tryptophan) isolated in thi s study 
(Table IV) accounted for less than 1% of the dose 
when D-t ryptophan-7a-C 14 was given. Isolated D-
tryptopha n-7a-C 14 accounted for 36% of the dose, 
but this left 25% of the dose unaccounted for in 
the urine. This residua l C 14 may represen t indole 
pyruvic acid and rela ted metabo.li tes which would 
be formed by the action of D-a mino ac id oxidase 
or other enzymes. 
Some of the sc leroderma patients used in thi s 
study had normal leve ls of urinary tryptophan 
metabolites as eva luated by the 2.0 gm load test. 
Previous L-tryptophan loading studies in sclero-
derma patients (4, 5) showed hi gh urina ry levels 
of kynurenine and less elevated leve ls of hydroxy-
kynurenine in so me patients, suggesting that such 
patients might have an inhibition of the. kynu-
renine hydroxylase system. In t he present study, 
on ly pat ient D-1 exh ibi ted ma rkedl y ab normal 
t ryptopha n metaboli sm in response to the load 
test (Table III) , and was appa rently not lacking in 
kynurenine hydroxy lase, s ince leve ls of hydroxy-
kynurenine a nd xa n thureni c ac id were also 
markedly elevated. When this patient was given 
L-kynurenine-keto-C 14 seven months later (pa -
tient D-2), she showed a depressed C "O , metabo-
. !is m (32%) compared to pat ient B-2 (53%), who 
a lso rece ived L-kynurenine-keto-C ", but who had 
a normal urinary excretion pattern after the 2.0 
gm tryptophan load test. The kynurenine and 
hydroxy kynurenine leve ls in patient D-2, after L-
kynurenine-keto-C '"', were elevated, but not as 
much as would be expected if the fault in trypto-
phan meta boli sm were in t he hydroxy lation of 
kynurenine. T hus there seems to be no demon-
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strable d efect in kynurenin e hydroxylation in thi s 
patient . 
The fact that the C" activity in a ll of the com -
ponents in the pathway (F ig. 1) above quinolinic 
ac id were two to ten t imes higher in the urine of 
patient D-2 tha n in the urine of patient B-2 sug-
gests a difference in her metaboli sm somewhere 
after hydroxykynurenine. This response to the L-
kynurenine-keto-C" dose cannot be expla ined by 
an adapted t ry ptophan oxygenase or 2.0 gm load 
stimula tion (24, 25) as cause for the increased 
levels of these components, s in ce the t ryptophan 
oxygenase enzyme step was by -passed when the 
s m all t racer doses of L-kynurenine were ad minis-
tered. 
The present studies using the D-isomer. of la-
beled t ry ptophan, kynurenine and hyd roxy kynu -
renine in sc leroderma pa t ients demonstrated that 
these isomers contr ibu te ve ry li ttle to the produc-
tion of C " 0 2 compared to that contri buted by 
th e natu ra l L-isomers. Consequently, in studies of 
CO, produ ct ion from t ryptophan metabo li tes in 
man, it would be possible to use read ily available 
DL-co mpounds with little error. However. these 
condi t ions would not be applicab le for thi type 
of study in rats, since this species seems to 
readi ly conve rt D-tryptophan to C0 2 (3), but not 
the in te rmedi ates D-kynurenine or D-hydroxy-
kynurenine ( 1, 2). 
T he concept of us ing a 2.0 gm "loading" dose 
of L-t ryptop ha n with a t racer dose of the labe led 
DL-trypto phan and measurin g C"0 2 production 
may st ill hold promise as a means of detecting 
ab normalit ies in tryptophan metabo lism in pa-
tien ts hav ing certa in d iseases. T he depressions in 
C 140 2 excretion observed in the presen t study, 
compared to the levels seen in previous studies 
(6), when DL-tryptophan-2-C" was given with a 
2.0 gm load of L-t rypto1 han, were not consistent 
enough to indicate a relationshi p between the 
presence of sc lerode rma a nd tryptophan metabo-
lism. More patients would have to be studied to 
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determine if a relationship exists between C "0 2 
production and clinica l status, diagnosis, prog-
nosis or urinary metabolites of tryptophan. 
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